Optogenetics in Humans Is Closer Than You Think — And It Will Start With the Eye

Optogenetics — controlling neurons with light-sensitive proteins — has been the workhorse of neuroscience for 15 years but has never been used therapeutically in humans. Until GenSight Biologics' PIONEER trial showed that AAV-delivered channelrhodopsin partially restored vision in a blind patient with retinitis pigmentosa (Sahel et al., 2021, Nature Medicine).
The retina is the ideal entry point: optically accessible, immune-privileged, and the target neurons (retinal ganglion cells) are well-characterized. But the real prize is the brain. Intracerebral optogenetics would offer cell-type-specific neural modulation that deep brain stimulation can't match.
Hypothesis: Clinical optogenetics will follow a retina-first, brain-second trajectory, with retinal prosthetics reaching FDA approval by 2028 and intracerebral optogenetics entering Phase I for treatment-resistant epilepsy by 2030. The critical enabler will be red-shifted opsins (ChRmine, Chrimson) that respond to near-infrared light capable of penetrating tissue without fiber optics.
Prediction: A wireless, fiber-free optogenetic system using transcranial near-infrared stimulation of ChRmine-expressing neurons will demonstrate proof-of-concept in non-human primates by 2027.